Shares of Glenmark Pharmaceuticals were trading in the green on 27 September after its subsidiary Glenmark Speciality SA signed an agreement with Cosmo Pharmaceuticals NV for the distribution and licence agreements for its acne cream in Europe and South Africa.

In this agreement, a subsidiary of Cosmo Pharmaceuticals, Cassiopeia, will grant the company exclusive rights to commercialise Winlevi in 15 EU countries, including the Netherlands, Spain, the United Kingdom, Finland, Norway, Denmark, and South Africa.

The company will be responsible for product registration in South Africa and the UK, and Cassiopea will be responsible for the centralised marketing authorisation at the EMA (European Medicines Agency).

Winlevi (clascoterone cream 1%) has been approved by the USFDA (the US Food and States Drug Administration) as a novel drug with a unique mechanism of action for the topical treatment of acne in patients aged 12 years and above.

The drug has become the most prescribed branded topical acne drug in the US and has over 88% of total dermatology having prescribed Winlei. It has become one of the most successful US launches in the topical acne space in the last 15 years.

Glenn Saldanha, Chairman & Managing Director of Glenmark Pharmaceuticals, said, “Winlevi is the perfect addition to our European dermatology portfolio and we look forward to leveraging our half-century-long experience in dermatology to make this novel option available to patients and fill the current unmet medical need in treating acne.”

At 2:50 pm, the shares of Glenmark Pharmaceutical were trading at Rs 778.25 or 2.10% above its previous close on NSE.